Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Shareholders' Deficit

v3.22.1
Consolidated Statements of Shareholders' Deficit - USD ($)
$ in Thousands
Share Capital [Member]
Contributed Surplus - Warrant Reserve [Member]
Contributed Surplus [member]
Deficit [Member]
Total
Beginning balance at Dec. 31, 2019 $ 194,217 $ 642 $ 8,304 $ (214,845) $ (11,682)
Beginning balance, share at Dec. 31, 2019 39,908       39,907,681
Statement Line Items [Line Items]          
Issuance of common shares, net of issuance costs $ 12,819       $ 12,819
Issuance of common shares, net of issuance costs, shares 23,924        
Issuance of broker warrants $ (1,029) 1,029      
Common stock equivalents converted $ 1       1
Common stock equivalents converted, shares 11,500        
Share issue expense $ (488)       (488)
Derivative warrants exercised $ 8,628       8,628
Derivative warrants exercised, shares 7,853        
Stock based compensation expense     1,097   1,097
Net loss and Comprehensive loss       (24,184) (24,184)
Ending balance at Dec. 31, 2020 $ 214,148 1,671 9,401 (239,029) $ (13,809)
Ending balance, shares at Dec. 31, 2020 83,185       83,184,843
Statement Line Items [Line Items]          
Derivative warrants exercised $ 8,000       $ 8,000
Derivative warrants exercised, shares 8,000        
Derivative warrants exercised - fair value adjustment $ 15,722       15,722
January 2021 Equity Offering, net of issuance costs $ 7,211 3,164     10,375
January 2021 Equity Offering, net of issuance costs, shares 7,419        
January 2021 Equity Offering-broker warrants $ (1,384) 1,384      
February 2021 Equity Offering, net of issuance costs $ 15,165 5,928     21,093
February 2021 Equity Offering, net of issuance costs, shares 9,585        
February 2021 Equity Offering-broker warrants $ (1,238) 1,238      
Equity warrants exercised $ 2,979 (994)     1,985
Equity warrants exercised, shares 1,319        
Equity warrants expired   (642) 642    
Stock options exercised $ 27   (12)   15
Stock options exercised, shares 20        
Issuance of common shares to Aspire $ 2,709       2,709
Issuance of common shares to Aspire, shares 1,600        
Issuance of common shares to consultant $ 25       25
Issuance of common shares to consultant, shares 75        
Stock based compensation expense     4,036   4,036
Net loss and Comprehensive loss       (14,858) (14,858)
Ending balance at Dec. 31, 2021 $ 263,364 $ 11,749 $ 14,067 $ (253,887) $ 35,293
Ending balance, shares at Dec. 31, 2021 111,203       111,202,690